Edwards Lifesciences (EW) Receivables - Other (2009 - 2026)

Edwards Lifesciences' Receivables - Other history runs 18 years deep, the most recent figure standing at $197.3 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 138.57% year-over-year to $197.3 million in Q1 2026; TTM through Mar 2026 was $197.3 million, a 138.57% increase from a year earlier, with the FY2025 full-year figure at $252.5 million, up 113.44% from the prior year.
• Receivables - Other eased to $197.3 million in Q1 2026 per EW's latest filing, from $252.5 million in the prior quarter.
• Across five years, Receivables - Other topped out at $252.5 million in Q4 2025 and bottomed at $42.8 million in Q2 2022.
• The 5-year median for Receivables - Other is $62.3 million (2023), against an average of $100.1 million.
• Across the five-year window, Receivables - Other plunged 35.78% in 2022 and jumped 266.49% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $56.1 million in 2022, then climbed by 0.89% to $56.6 million in 2023, then jumped by 109.01% to $118.3 million in 2024, then soared by 113.44% to $252.5 million in 2025, then retreated by 21.86% to $197.3 million in 2026.
• Per Business Quant, the three latest EW Receivables - Other figures stand at $197.3 million (Q1 2026), $252.5 million (Q4 2025), and $199.5 million (Q3 2025).